Technical Analysis for GNBT - Generex Biotechnology Corporatio

Grade Last Price % Change Price Change
grade C 0.5815 -1.16% -0.0068
GNBT closed down 1.16 percent on Tuesday, July 7, 2020, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical GNBT trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Spinning Top Other 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Older signals for GNBT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at or the Antigen Express website at
Medicine Medical Specialties Branches Of Biology Cancer Immune System Autoimmune Diseases Immunotherapy Drug Delivery Platform Technology Platform Technologies Drug Delivery Systems Antigen T Cell

Is GNBT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.25
52 Week Low 0.4
Average Volume 311,613
200-Day Moving Average 0.8543
50-Day Moving Average 0.5665
20-Day Moving Average 0.5955
10-Day Moving Average 0.6066
Average True Range 0.0750
ADX 32.6
+DI 22.4652
-DI 7.7334
Chandelier Exit (Long, 3 ATRs ) 0.5750
Chandelier Exit (Short, 3 ATRs ) 0.7250
Upper Bollinger Band 0.6648
Lower Bollinger Band 0.5262
Percent B (%b) 0.4
BandWidth 23.2746
MACD Line 0.0092
MACD Signal Line 0.0111
MACD Histogram -0.0019
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.6210
Resistance 3 (R3) 0.6229 0.6118 0.6144
Resistance 2 (R2) 0.6118 0.6017 0.6108 0.6122
Resistance 1 (R1) 0.5966 0.5955 0.5911 0.5947 0.6100
Pivot Point 0.5855 0.5855 0.5827 0.5845 0.5855
Support 1 (S1) 0.5703 0.5754 0.5648 0.5684 0.5530
Support 2 (S2) 0.5592 0.5692 0.5582 0.5508
Support 3 (S3) 0.5440 0.5592 0.5486
Support 4 (S4) 0.5421